PSP - Unmatched sepsis biomarker

Pancreatic Stone Protein

CAL02 - First-in-class life-saving drug

Results in severe pneumonia patients ranked “a medical breakthrough”.
The Lancet Infectious Diseases 
(Laterre et al. 2019; Pletz et al. 2019)

The company’s portfolio is currently composed of two critical care products based on innovative technologies and aiming at fighting sepsis and treating severe bacterial and viral infections.

Restoring health in critically ill patients

suffering of severe infection

Early detection of sepsis

and severity prediction